Metformin Against Aging: Promising, but Old Animals Raise Doubts
Graded Preliminary — a review that summarizes existing lab, animal and human observational research without adding new data of its own.
- Design
- Narrative review
- Participants
- N/A
- Duration
- —
- Funding
- —
Metformin acts on several aging-related processes in cells, but studies in old animals also hint at harmful effects.
No drug has yet been approved to slow aging itself, despite more than 15 years of research and hundreds of tested compounds. A new review turns to a familiar pill: metformin, a standard treatment for type 2 diabetes. According to the authors, people taking metformin died less often and developed several age-related diseases less often. They say this also holds for people without diabetes, regardless of blood sugar.
Inside cells, the review describes metformin acting on several processes linked to aging. It switches on AMPK, an enzyme that works like the cell's energy sensor. It dampens mTOR, a growth switch, and supports the cell's own cleanup system. The authors also list better-working mitochondria, the cell's power plants, and fewer inflammatory signals from aged cells. Large observational studies, they write, fit this picture.
The authors also point to contradictions. In old animals, metformin may even affect aging in a harmful way. How the drug works in detail is not fully understood. The review gathers existing research and adds no new data. Observational studies show links, not whether metformin itself is the cause.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.